Prostate Cancer News on BioPortfolio

GUProstate Cancer Medscape

Review indepth clinical information latest medical news and guidelines on prostate cancer and prostate cancer treatment including prostate cancer surgery. Learn about prostate cancer prognosis for advanced prostate cancer.

Nymox Reports 78 Month Results From Biopsy and Surgery Confirmed Prospective Randomized NX030040 Prostate Cancer Study of Fexapotide Triflutate Gleason Grade Progression Reduced by 81 Overall and Fexapotide 15mg Minimal Treatment Leads to 73 LongTerm

HASBROUCK HEIGHTS N.J. Oct. 09 2018 GLOBE NEWSWIRE Nymox Pharmaceutical Corporation NASDAQ NYMX is pleased to announce today important new longterm clinical trial results from the Company's 146 patient Phase IIb NX030040 Fexapotide FT U.S. study for low...

CXC Chemokine Receptor Type 4 FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4 Pipeline Review H2 2018

CXC Chemokine Receptor Type 4 FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4 Pipeline Review H2 2018Sum...

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A SerineThreonine Kinase MNB or MNBDYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1 Pipeline Review H2 2018 Re

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A SerineThreonine Kinase MNB or MNBDYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1 Pipeline Review H2 2018SummaryA...

Pages